{"count": 6, "results": [{"_id": "20566677", "pmid": 20566677, "pmcid": "PMC2928341", "title": "Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes", "journal": "Diabetes Care", "authors": ["Ruggenenti P", "Cattaneo D", "Rota S", "Iliev I", "Parvanova A", "Diadei O", "Ene-Iordache B", "Ferrari S", "Bossi AC", "Trevisan R", "Belviso A", "Remuzzi G", "Ezetimibe and Simvastatin in Dyslipidemia of Diabetes (ESD) Study Group"], "date": "2010-09-01T00:00:00Z", "doi": "10.2337/dc10-0320", "meta_date_publication": "2010 Sep", "meta_volume": "33", "meta_issue": "9", "meta_pages": "1954-6", "score": 50077.207, "text_hl": "In a multicenter prospective randomized double-blind placebo-controlled trial, we primarily compared by ANCOVA the effect of 2-month @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@ (10 mg/day) or placebo therapy on LDL cholesterol serum levels in 108 @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@type 2 diabetic@@@ @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@ <200 mug/min and total @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@cholesterol@@@ concentrations >135 mg/dl despite @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ treatment (40 mg/day).", "citations": {"NLM": "Ruggenenti P, Cattaneo D, Rota S, Iliev I, Parvanova A, Diadei O, Ene-Iordache B, Ferrari S, Bossi AC, Trevisan R, Belviso A, Remuzzi G, Ezetimibe and Simvastatin in Dyslipidemia of Diabetes (ESD) Study Group. Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes Diabetes Care. 2010 Sep;33(9):1954-6. PMID: 20566677", "BibTeX": "@article{20566677, title={Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes}, author={Ruggenenti P and Cattaneo D and Rota S and Iliev I and Parvanova A and Diadei O and Ene-Iordache B and Ferrari S and Bossi AC and Trevisan R and Belviso A and Remuzzi G and Ezetimibe and Simvastatin in Dyslipidemia of Diabetes (ESD) Study Group}, journal={Diabetes Care}, volume={33}, number={9}, pages={1954-6}}"}}, {"_id": "24244596", "pmid": 24244596, "pmcid": "PMC3828237", "title": "Simvastatin Alleviates Hyperpermeability of Glomerular Endothelial Cells in Early-Stage Diabetic Nephropathy by Inhibition of RhoA/ROCK1", "journal": "PLoS One", "authors": ["Peng H", "Luo P", "Li Y", "Wang C", "Liu X", "Ye Z", "Li C", "Lou T"], "date": "2013-11-14T00:00:00Z", "doi": "10.1371/journal.pone.0080009", "meta_date_publication": "2013", "meta_volume": "8", "meta_issue": "11", "meta_pages": "e80009", "score": 50058.254, "text_hl": "Furthermore, we found that the early abnormalities of GEnCs, as well as @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@, can be reversed by @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ treatment.", "citations": {"NLM": "Peng H, Luo P, Li Y, Wang C, Liu X, Ye Z, Li C, Lou T. Simvastatin Alleviates Hyperpermeability of Glomerular Endothelial Cells in Early-Stage Diabetic Nephropathy by Inhibition of RhoA/ROCK1 PLoS One. 2013;8(11):e80009. PMID: 24244596", "BibTeX": "@article{24244596, title={Simvastatin Alleviates Hyperpermeability of Glomerular Endothelial Cells in Early-Stage Diabetic Nephropathy by Inhibition of RhoA/ROCK1}, author={Peng H and Luo P and Li Y and Wang C and Liu X and Ye Z and Li C and Lou T}, journal={PLoS One}, volume={8}, number={11}, pages={e80009}}"}}, {"_id": "1521727", "pmid": 1521727, "title": "Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.", "journal": "Diabetologia", "authors": ["Hommel E", "Andersen P", "Gall MA", "Nielsen F", "Jensen B", "Rossing P", "Dyerberg J", "Parving HH"], "date": "1992-05-01T00:00:00Z", "doi": "10.1007/BF02342442", "meta_date_publication": "1992 May", "meta_volume": "35", "meta_issue": "5", "meta_pages": "447-51", "score": 50057.047, "text_hl": "Total @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@cholesterol@@@, LDL-cholesterol, HDL-cholesterol, @GENE_APOA1 @GENE_335 @@@apolipoprotein A-I@@@, @GENE_APOB @GENE_338 @@@apolipoprotein B@@@ remained unchanged during placebo treatment. @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@Albuminuria@@@ measured during the @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ and the placebo treatment (baseline vs 12 weeks) (the data are logarithmically transformed before analysis because of their positively skewed transformation; geometric mean (x/divided by antilog SE) is indicated) was 458 (x/divided by 1.58) vs 393 (x/divided by 1.61) and 481 (x/divided by 1.62) vs 368 (x/divided by 1.78 micrograms/min (NS). ", "citations": {"NLM": "Hommel E, Andersen P, Gall MA, Nielsen F, Jensen B, Rossing P, Dyerberg J, Parving HH. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia. 1992 May;35(5):447-51. PMID: 1521727", "BibTeX": "@article{1521727, title={Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.}, author={Hommel E and Andersen P and Gall MA and Nielsen F and Jensen B and Rossing P and Dyerberg J and Parving HH}, journal={Diabetologia}, volume={35}, number={5}, pages={447-51}}"}}, {"_id": "17878758", "pmid": 17878758, "title": "Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine.", "journal": "J Cardiovasc Pharmacol", "authors": ["Rugale C", "Delbosc S", "Mimran A", "Jover B"], "date": "2007-09-01T00:00:00Z", "doi": "10.1097/FJC.0b013e3180a72606", "meta_date_publication": "2007 Sep", "meta_volume": "50", "meta_issue": "3", "meta_pages": "293-8", "score": 50054.734, "text_hl": "Only @CHEMICAL_Hydralazine @CHEMICAL_MESH:D006830 @@@hydralazine@@@ lowered @GENE_AGT @GENE_24179 @@@AngII@@@ @DISEASE_Hypertension @DISEASE_MESH:D006973 @@@hypertension@@@. @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ and @CHEMICAL_acetovanillone @CHEMICAL_MESH:C056165 @@@apocynin@@@ lowered @DISEASE_Cardiomegaly @DISEASE_MESH:D006332 @@@cardiac hypertrophy@@@ by 52% and 54% and reversed the marked rise in @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@ by 25% and 70%. ", "citations": {"NLM": "Rugale C, Delbosc S, Mimran A, Jover B. Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine. J Cardiovasc Pharmacol. 2007 Sep;50(3):293-8. PMID: 17878758", "BibTeX": "@article{17878758, title={Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine.}, author={Rugale C and Delbosc S and Mimran A and Jover B}, journal={J Cardiovasc Pharmacol}, volume={50}, number={3}, pages={293-8}}"}}, {"_id": "19906952", "pmid": 19906952, "title": "Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension.", "journal": "Am J Physiol Renal Physiol", "authors": ["Knight SF", "Yuan J", "Roy S", "Imig JD"], "date": "2010-01-01T00:00:00Z", "doi": "10.1152/ajprenal.00351.2009", "meta_date_publication": "2010 Jan", "meta_volume": "298", "meta_issue": "1", "meta_pages": "F86-94", "score": 50054.156, "text_hl": "@CHEMICAL_tempol @CHEMICAL_MESH:C001803 @@@Tempol@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ treatment significantly ameliorated @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@ in the SHR fed a high-fat diet. ", "citations": {"NLM": "Knight SF, Yuan J, Roy S, Imig JD. Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. Am J Physiol Renal Physiol. 2010 Jan;298(1):F86-94. PMID: 19906952", "BibTeX": "@article{19906952, title={Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension.}, author={Knight SF and Yuan J and Roy S and Imig JD}, journal={Am J Physiol Renal Physiol}, volume={298}, number={1}, pages={F86-94}}"}}, {"_id": "18083785", "pmid": 18083785, "title": "Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.", "journal": "Diabetes", "authors": ["Kolavennu V", "Zeng L", "Peng H", "Wang Y", "Danesh FR"], "date": "2008-03-01T00:00:00Z", "doi": "10.2337/db07-1241", "meta_date_publication": "2008 Mar", "meta_volume": "57", "meta_issue": "3", "meta_pages": "714-23", "score": 50049.062, "text_hl": "Interestingly, @CHEMICAL_Blood_Glucose @CHEMICAL_MESH:D001786 @@@blood glucose@@@ was unaffected by @CHEMICAL_fasudil @CHEMICAL_MESH:C049347 @@@fasudil@@@ administration. Treatment with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ significantly attenuated @GENE_RHOA @GENE_11848 @@@RhoA@@@ activation in the kidney cortices of db/db @SPECIES_10090 @@@mice@@@ and resulted in a significant reduction of @<m>DISEASE_Albuminuria</m> @DISEASE_MESH:D000419 @@@albuminuria@@@ and mesangial matrix expansion. ", "citations": {"NLM": "Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes. 2008 Mar;57(3):714-23. PMID: 18083785", "BibTeX": "@article{18083785, title={Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.}, author={Kolavennu V and Zeng L and Peng H and Wang Y and Danesh FR}, journal={Diabetes}, volume={57}, number={3}, pages={714-23}}"}}]}